Parvoruvax
Ceva, France
Vaccine against swine erysipelas and porcine parvovirosis

Composition:
Each dose of 2 ml contains:
Inactivated porcine parvovirus ................................................................................ ... ≥ 2 HAI.U1
Erysipelothrix rhusiopathiae, serotype 2, (lysed bacterial cells) ................................... ≥ 1 ELISA U.2
Aluminium hydroxide (expressed in Al+++) ....................................................................... 4.2 mg.
Thiomersal ..................................................................................................................≤ 0.2 mg.

1 HAI.U: q.s. to obtain HAI antibody titres of 1 log10 in guinea-pigs after administration of the vaccine.
2 ELISA U.: qs to obtain in animals a seroconversion index (ELISA) compliant with European Pharmacopoeia.

Indications:
In breeder and future breeder pig:
- Active immunisation against swine erysipelas.
- Active immunisation against porcine parvovirosis.

*The inactivated adjuvanted vaccine induces an immune status against porcine parvovirosis and swine erysipelas.

Administration route:
One 2 ml dose by deep intramuscular route behind the ear, according to the following schedule: Primary vaccination:  In the absence of maternally derived antibodies to porcine parvovirus:
2 injections with a 3- to 4-week interval, the second injection being performed at least 1week before service mating. In case of unknown status as regards maternally derived antibodies to porcine parvovirus: use RUVAX and PARVOVAX vaccines. PARVORUVAX vaccine can, only be used for booster vaccination.
Booster: Every six months (in females, during the week preceding weaning).

Contra indication:
Primary vaccination against porcine parvovirosis of pigs less than 6 months of age in the presence of maternally derived antibodies.

Withdrawal period: Zero days.

Storage:
Store and transport at a temperature between +2°C and +8°C, protected from light.